EGFR and non-small cell lung carcinoma: Although EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib provide a therapeutic benefit in treating patients with NSCLC, particularly those with EGFR mutations, most patients eventually develop resistance to such targeted therapies[2,3].